VLS Valneva SE

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Saint-Herblain (France), March 25, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.25-0140 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).

Valneva’s 2024 Universal Registration Document – available in its entirety in French – includes the Company’s 2024 Annual Financial Report, the Company's Annual Management Report, the Board of Directors’ Corporate Governance Report and the Company’s Sustainability Statement. The Sustainability Statement is available in both English and French.

These documents are available on Valneva’s website () and will also be available on the AMF () and SEC () websites, respectively. Hard copies of these documents may be obtained from the Company, free of charge, upon request at the following address: 6 rue Alain Bombard, 44800 Saint-Herblain, France.

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.

We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first chikungunya vaccine, as well as certain third-party vaccines.

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at .







Valneva Investor and Media Contacts

Laetitia Bachelot-Fontaine

VP, Global Communications and European Investor Relations

M +33 (0)6 4516 7099



















Joshua Drumm, Ph.D.

VP, Global Investor Relations

M 20













        		 

Attachment



EN
25/03/2025

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE
Free
VLS VALNEVA SE

VALNEVA Declaration of shares and voting rights: August 31, 2025

VALNEVA Declaration of shares and voting rights: August 31, 2025 VALNEVA Declaration of shares and voting rights August 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: September 3, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number...

September 3, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

VALNEVA Déclaration d’actions et de droits de vote : 31 août 2025

VALNEVA Déclaration d’actions et de droits de vote : 31 août 2025 VALNEVA Déclaration d’actions et de droits de vote 31 août 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 3 septembre 2025 Nombre d’actions composant le capital de ValnevaNombre total de droits de vote incluant les droits de vote suspendus*Origine de la variationDate à laquelle cette variation a été const...

September 3, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Res...

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypesNo safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with previous booster results. Saint-Herblain (France), September 3rd, 2025 –  (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. ...

September 3, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva annonce de nouvelles données positives d’innocuité et d’immuno...

Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme  Forte réponse immunitaire chez les enfants et les adultes après la troisième vaccination annuelle de rappelForte réponse anamnestique observée pour les six sérotypes Aucun problème de sécurité observé dans toutes les tranches d’âge par le comité indépendant de surveillance des données (DMC), comme pour les précédents résultats de rappel Saint-Herblain (France), le 3 Septembre, 2025 –  (Nasdaq: VALN; Euronext Paris: VLA) a annoncé aujourd’hui des donné...

September 3, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vac...

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. Saint Herblain (France), August 25, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ®, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of IXCHIQ® in the United States. The suspension follows the FDA’s decisio...

August 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch